VivoSeq
Other

Gene Polymorphism

0

Pipeline Programs

1

Active Trials

0

Companies Involved

Gene Polymorphism is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

14/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

14

clinical trials

Completed6 · 43%
Unknown status5 · 36%
Terminated2 · 14%
Recruiting1 · 7%

Trial Activity

14 trials

VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management
Unknown status··N/A·NCT00970892·500 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)